Piramal Pharma Board Approves FY26 Audited Results, Reappoints Key Directors
Piramal Pharma Limited approved its audited financial results for FY26. The company reported a profit after tax of ₹700.01 crore for the year ended March 31, 2026. Key appointments include Ms. Nandini Piramal as Executive Director & Chairperson and Mr. Maneesh Sharma as Company Secretary. Re-appointments of directors were also approved.
The re-appointment of key leadership and approval of financial results are significant for corporate governance and future strategy, impacting stakeholder confidence.
The approval of audited financial results, re-appointment of key directors and management, and an unmodified auditor's report indicate stability and positive governance.
Piramal Pharma Limited announced the outcome of its Board Meeting held on April 28, 2026. The Board approved the Audited Financial Statements (Standalone & Consolidated) for the financial year ended March 31, 2026, along with the results for the quarter and financial year ended March 31, 2026. The company also confirmed that the Statutory Auditors' Report on these results received an unmodified opinion.
In significant personnel decisions, the Board approved the re-appointment of Ms. Nandini Piramal as Whole-Time Director, designated as Executive Director and Chairperson, for a further period of three years effective April 1, 2027. Additionally, Mr. Peter DeYoung was re-appointed as Whole-Time Director, designated as Executive Director, for a period of three years effective October 6, 2026. The Board also approved the re-appointment of Mr. Sridhar Gorthi as a Non-Executive, Independent Director for a second term of five years effective March 30, 2027, and Mr. Peter Stevenson as a Non-Executive, Independent Director for a second term of five years effective March 30, 2027, also approving his continuation post-attaining the age of 75.
Furthermore, Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer, a Key Managerial Personnel (KMP), effective April 29, 2026. Consequently, Ms. Pratibha Mishra ceases to be the Interim Company Secretary and Compliance Officer. The Board also approved a change in the registered office address of the Company, effective April 30, 2026.
The standalone financial results for the year ended March 31, 2026, show a profit after tax of ₹700.01 crore, compared to ₹691.40 crore in the previous year. Revenue from operations for the year stood at ₹4,782.01 crore, a decrease from ₹5,285.71 crore in the prior year. For the quarter ended March 31, 2026, profit after tax was ₹261.63 crore on revenue from operations of ₹1,489.06 crore.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.